Edge Therapeutics Inc
0 DAYS LEFT TO SEEK LEAD PLAINTIFF STATUS
Case Summary | |
Company Name: | Edge Therapeutics Inc |
Stock Symbol : | NASDAW: EDGE |
Class Period Start: | 12/29/2017 |
Class Period End: | 03/27/2018 |
Lead Plaintiff motion: | 06/22/2018 |
Date Filed: | 04/23/2018 |
Type of Case: | Securities Class Action |
Court: | U.S. District Court for the District of New Jersey |
Summary: | Thieler Law Corp advises investors with losses exceeding $100,000 of the June 22, 2018 lead plaintiff deadline in a class action lawsuit filed against Edge Therapeutics Inc (NASDAW: EDGE) (“Edge Therapeutics” or “the Company”). The suit is pending in the U.S. District Court for the District of New Jersey and investors, who purchased Edge Therapeutics Inc securities between December 29, 2017 and March 27, 2018, have until June 22, 2018 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class. If you purchased Edge Therapeutics Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class. The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that the Company’s lead product candidate EG-1962 would likely fail a futility analysis in connection with the NEWTON 2 study; and that, as a result of the foregoing, the Company’s financial statements and Defendants’ statements about Edge’s business, operations, and prospects, were materially false and misleading at all relevant times. On March 28, 2018, the Company issued a press release reporting the discontinuation of the Phase 3 NEWTON 2 study, citing a low probability that EG-1962 would achieve a statistically-significant difference compared to the standard of care in the study’s primary endpoint. Following this news, NASDAW: EDGE fell from $15.59 per share on March 27, 2018 to a closing price of $1.31 on March 28, 2018—a $14.28 or a 91.59% drop. If you were negatively impacted by your investment in Edge Therapeutics Inc securities between December 29, 2017 and March 27, 2018 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation. Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Thieler Law Corp 2534 State Street - Suite 406, San Diego, CA 92101 by email: mail@thielerlaw.com or telephone at +1 (619) 377 - 4324 or visit our website http://www.thielerlaw.com/ or Facsimile: +1 (619) 785 – 3185 |